1 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell MalignanciesPart 1:r/r B-cell Malignancies; Part 2:B-cell MalignanciesActive, not recruitingPhase 1 / Phase 22026-06-08NCT04014205